“DT56a … unique nature compared to the compounds currently used for postmenopausal osteoporosis by being bone-forming and not only an anti-resorptive agent.”
DT56a stimulates gender-specific human cultured bone cells in vitro.
DT56a stimulated CK and DNA synthesis in both pre- and post-menopausal female Ob with
maximal effect at 100 ng/ml for both age groups. In addition, DT56a stimulated ALP in Ob
from both pre- and post-menopausal women with maximal effect at lower dose of 50 ng/ml,
with higher response of pre-menopausal cells. Raloxifene (Ral) inhibited all DT56a-
stimulated changes in Ob from both age groups. DT56a, when given together with E2,
completely antagonized E2-stimulated effects demonstrating its nature as a phyto-SERM.
DT56a also, dose dependency, stimulated the intracellular levels of [Ca(2+)](i) with maximal
effect at 10 ng/ml. Male-derived Ob did not respond to DT56a in any parameter. In
summary, DT56a stimulated sex-specifically female-derived Ob, indicating its unique nature
compared to the compounds currently used for postmenopausal osteoporosis by being
bone-forming and not only an anti-resorptive agent.